Results 51 to 60 of about 56,186 (320)
First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]
, 2016 The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F. +3 more
core +2 more sources
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Nature Communications, 2016 Aromatase inhibitors are used to treat oestrogen receptor positive breast cancers but the molecular basis for the response of patients is unclear. Here, the authors use samples from an aromatase inhibitor clinical trial and show that tumours from poor ...
Pascal Gellert +25 more
doaj +1 more source
Effects of a saponin fraction extracted from Trigonella foenum-graecum L. and two commercially available saponins on sex ratio and gonad histology of Nile tilapa fry, Oreochromis niloticus (L.) [PDF]
, 2013 Over three million tonnes (t) of tilapia, mostly Nile tilapia (Oreochromis niloticus, L.), are produced annually making it the second most abundantly produced freshwater fish (FAO, 2010).
Abu-Lafi, S. +8 more
core
Decreased risk of breast cancer associated with oral bisphosphonate therapy [PDF]
, 2012 Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their ...
Brufsky, A, Mathew, A
core +2 more sources
Drug Testing and Analysis, EarlyView.New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley +1 more source
Managing menopausal symptoms and associated clinical issues in breast cancer survivors [PDF]
, 2017 Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and
Davis, Susan R. +5 more
core +1 more source
Drug Testing and Analysis, EarlyView.The study developed a single Abnormal Steroid Profile Score (ASPS) to improve interpretation of the Athlete Biological Passport steroid module. Using Bayesian modelling and logistic regression, biomarker patterns from laboratory and doping control data successfully discriminated between doped and clean individuals, with improved classification ...
James G. Hopker +3 more
wiley +1 more source
Celecoxib in breast cancer prevention and therapy. [PDF]
, 2018 Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively
Cao, Wei +4 more
core
A non-synonymous coding change in the CYP19A1 gene Arg264Cys (rs700519) does not affect circulating estradiol, bone structure or fracture [PDF]
, 2011 Background The biosynthesis of estrogens from androgens is catalyzed by aromatase P450 enzyme, coded by the CYP19A1 gene on chromosome 15q21.2. Genetic variation within the CYP19A1 gene sequence has been shown to alter the function of the enzyme.
Wang, J.Z. +8 more
core +3 more sources